A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaResearch in context

Summary: Background: Sarcomas represent an extensive group of malignant diseases affecting mesodermal tissues. Among sarcomas, the clinical management of chondrosarcomas remains a complex challenge, as high-grade tumours do not respond to current therapies. Mutations in the isocitrate dehydrogenase...

Full description

Bibliographic Details

Published in:	EBioMedicine
Main Authors:	Verónica Rey, Juan Tornín, Juan Jose Alba-Linares, Cristina Robledo, Dzohara Murillo, Aida Rodríguez, Borja Gallego, Carmen Huergo, Cristina Viera, Alejandro Braña, Aurora Astudillo, Dominique Heymann, Karoly Szuhai, Judith V.M.G. Bovée, Agustín F. Fernández, Mario F. Fraga, Javier Alonso, René Rodríguez
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Subjects:	Chondrosarcoma Enasidenib IDH2 Patient-derived models Personalized medicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396424001257